The Global Metastatic Melanoma Therapeutics Market, by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Surgery), by Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), by End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America), is estimated to be valued at US$ 6,432.3 Million in 2021 and is projected to exhibit a CAGR of 11.6% during the forecast period (2021-2028).
The increasing number of product launches and approvals by regulatory authorities is driving the global metastatic melanoma therapeutics market growth. For instance, on July 31, 2020, Roche, a swiss multinational healthcare company, announced that they received the U.S. Food and Drug Administration (FDA) approval for Tecentriq (atezolizumab), which is a monoclonal antibody, Cotellic (cobimetinib) that inhibits MEK1/2 proteins and Zelboraf (vemurafenib) which inhibits BRAF, for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
Global Metastatic Melanoma Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
COVID-19 pandemic has negatively affected metastatic melanoma therapeutics market globally. The players operating in the Global Metastatic Melanoma Therapeutics Market are facing major challenges on various fronts due to the COVID-19 pandemic. COVID-19 has affected the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of medical instruments from one place to another.
Delivering care to patients suffering from cancer during this crisis is challenging due to competing risks of death from cancer versus death or serious complications from SARS-CoV-2, and the likely higher risk of COVID-19 in immune compromised hosts. Furthermore, players operating in the Global Metastatic Melanoma Therapeutics Market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing matrices due to irregularities in transportation facility.
Browse 35 Market Data Tables and 36 Figures spread through 168 Pages and in-depth TOC on “Global Metastatic Melanoma Therapeutics Market, by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Surgery), by Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), by End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Forecast to 2028”.
To know the latest trends and insights prevalent in the Metastatic Melanoma Therapeutics Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/metastatic-melanoma-therapeutics-market-4608
Increasing number of product launches and approvals by regulatory authorities is expected to propel the growth of the global metastatic melanoma therapeutics market over the forecast period. For instance, on July 24, 2017, Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Yervoy (ipilimumab) injection for intravenous treatment of metastatic melanoma in children patients 12 years of age and older
Key Takeaways of the Global Metastatic Melanoma Therapeutics Market:
- The global metastatic melanoma therapeutics market is expected to exhibit a CAGR of 11.6% during the forecast period, owing to the increasing incidences of melanoma. Melanoma is more likely to occur as people get older. It can, however, develop in younger persons, including those under the age of 30. For instance, according to the Editorial Board of Cancer.Net, approximately 2,400 cases of melanoma were diagnosed in adults aged 15 to 29 in the United States in 2020.
- Among therapy, immunotherapy segment is expected to drive the global metastatic melanoma therapeutics market growth. Immunotherapy is the use of medicines to stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. For instance, Merck, a German multinational science and technology company, stated on February 19, 2019, that the U.S. Food and Drug Administration (FDA) approved Keytruda, Merck's anti-PD-1 medication, for the adjuvant treatment of patients with melanoma with lymph node(s) involvement following full resection.
- Major players operating in the global metastatic melanoma therapeutics market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences, AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
